Trialbee Partners With Savvy Cooperative
Trialbee has announced a strategic partnership with Savvy Cooperative. This partnership primarily addresses two pain points for patients—the challenge of finding appropriate clinical trials and the lack of opportunity to express their experiences to the industry as consumers of healthcare—an area still ripe for disruption.
As a practical example, Savvy Cooperative members will be introduced to specific clinical trials with an invitation to participate in pre-screening and referral to sites via the Trialbee Honey platform. At the end of the process, all potential participants who come through Honey, regardless of channel, will be invited to join the #AskPatients™ community to share their experiences for future research. While the collaboration is inclusive of all members in the Savvy community, lupus and multiple sclerosis have been selected as pilot indications to demonstrate the power of the partnership as these patients are simultaneously active yet traditionally under recruited.
Reference
Trialbee Partners with Savvy Cooperative to Bring the Voice of the Patient into Clinical Trials Earlier. (2023, March 29). Cision PRWeb.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
